

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))


Docket No.
19781

In Re Application Of: **Angeline Ingrid Bartholomeusz, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,906	April 21, 2006	Unassigned	23389	1645	7415

Title:

HBV VARIANTS DETECTION AND APPLICATION



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
 - the statement specified in 37 CFR 1.97(e);

OR

- the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 19781

In Re Application of: **Angeline Ingrid Bartholomeusz, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/576,906	April 21, 2006	Unassigned	23389	1645	7415

Title:

OBV VARIANTS DETECTION AND APPLICATION



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.
 - Charge the amount of _____
 - Credit any overpayment.
 - Charge any additional fee required.
- Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

April 12, 2007

(Date)

Signature of Person Mailing Correspondence

Xiaochun Zhu

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


 Signature

Dated: April 12, 2007

Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
 400 Garden City Plaza, Suite 300
 Garden City, New York 11530
 516-742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Angeline Ingrid Bartholomeusz, et al. **Examiner:** Unassigned

Serial No.: 10/576,906 **Art Unit:** 1645

Filed: April 21, 2006 **Docket:** 19781

For: HBV VARIANTS DETECTION
AND APPLICATION **Dated:** April 12, 2007

Confirmation No.: 7415

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Chen W.N. et al., "Human Hepatitis B Virus Mutants: Significance of Molecular Changes", *FEBS Letters* 453(3):237-242 (1999), XP004259880;
2. Stuyver L.J. et al., "Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region", *Hepatology* 33(3):751-757 (2001), XP009029630;
3. PCT International Publication No. WO 01/94559 A1, published December 13, 2001;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: April 12, 2007




Xiaochun Zhu

4. Bartholomew M.M. et al., "Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection After Orthotopic Liver Transplant Ation", *Lancet* 349(9044):20-22 (1997), XP004843545;
5. Bartholomeusz A. et al., "Mutations in the Hepatitis B Virus Polymerase Gene that are Associated with Resistance to Famciclovir and Lamivudine", *International Antiviral News* 5(8):123-124 (1997), XP002044248;
6. Alestig E. et al., "Phylogenetic Origin of Hepatitis B Virus Strains with Precore C-1858 Variant", *Journal of Clinical Microbiology* 39(9):3200-3203 (2001), XP002419805; and
7. Günther S. et al., "Analysis of Hepatitis B Virus Populations in an Interferon- α -Treated Patient Reveals Predominant Mutations in the C-Gene and Changing e-Antigenicity", *Virology* 244(1):146-160 (1998), XP004845022.

References 1-3 were cited in a Supplementary Partial Search Report dated December 12, 2006 received from the European Patent Office. References 1-7 were cited in a Supplementary Partial Search Report dated February 26, 2007 received from the European Patent Office. Applicants are submitting copies of the above-cited references as well as copies of the Search Reports. The relevance of the above-identified references has been described in the Supplementary Partial Search Reports.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no petition, certification or fee is required.

Respectfully submitted,



Xiaochun Zhu

Registration No. 56,311

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza, Suite 300
Garden City, New York 11530
(516) 742-4343
XZ:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)		Application Number			
LIST OF PRIOR ART CITED BY APPLICANT		19781		10/576,906			
<i>(Use several sheets if necessary.) ONE 1 APR 16 2007 PATENT & TRADEMARK OFFICE</i>		<i>APR 16 2007 PATENT & TRADEMARK OFFICE</i>		Applicant(s) Angeline Ingrid Bartholomeusz, et al.			
		Filing Date April 21, 2006		Group Art Unit 1645			
FOREIGN PATENT DOCUMENTS							
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/94559 A1	12/13/01	PCT			<input checked="" type="checkbox"/>	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Chen W.N. et al., "Human Hepatitis B Virus Mutants: Significance of Molecular Changes", <i>FEBS Letters</i> 453(3):237-242 (1999), XP004259880						
	Stuyver L.J. et al., "Nomenclature for Antiviral-Resistant Human Hepatitis B Virus Mutations in the Polymerase Region", <i>Hepatology</i> 33(3):751-757 (2001), XP009029630						
	Bartholomew M.M. et al., "Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection After Orthotopic Liver Transplant Ation", <i>Lancet</i> 349(9044):20-22 (1997), XP004843545						
	Bartholomeusz A. et al., "Mutations in the Hepatitis B Virus Polymerase Gene that are Associated with Resistance to Famciclovir and Lamivudine", <i>International Antiviral News</i> 5(8):123-124 (1997), XP002044248						
	Alestig E. et al., "Phylogenetic Origin of Hepatitis B Virus Strains with Precore C-1858 Variant", <i>Journal of Clinical Microbiology</i> 39(9):3200-3203 (2001), XP002419805						
	Günther S. et al., "Analysis of Hepatitis B Virus Populations in an Interferon- α -Treated Patient Reveals Predominant Mutations in the C-Gene and Changing e-Antigenicity", <i>Virology</i> 244(1):146-160 (1998), XP004845022						
EXAMINER			DATE CONSIDERED				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							